Springworks Therapeutics, Inc.

As of February 27, 2024, Springworks Therapeutics, Inc. is considered risky and overvalued due to high financial metrics like a Price to Book Value of 8.45 and negative returns on capital and equity, despite a year-to-date stock performance of 30.06% that exceeds the S&P 500's return.

As of February 27, 2024, Springworks Therapeutics, Inc. is considered a risky investment due to its overvaluation, reflected in a price-to-book ratio of 8.45, an EV to EBITDA ratio of -12.42, and a return on equity of -59.66%, despite a strong year-to-date return of 30.00%.

As of June 17, 2025, the trend is bullish with strong indicators like a bullish MACD and daily moving averages, though mildly tempered by a bearish signal from Bollinger Bands and mixed signals from KST and Dow Theory.

As of March 2022, the management team of Springworks Therapeutics, Inc. includes Mr. Daniel Lynch (Independent Chairman), Mr. Saqib Islam (CEO and Director), and Dr. Stephen Squinto (Acting Head of R&D and Director), along with Independent Directors Mr. Alan Fuhrman, Dr. Freda Lewis-Hall, and Mr. Jeffrey Schwartz.

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and cancer. As of March 2025, it reported net sales of $49 million and a net loss of $83 million, with a market cap of approximately $3.53 billion.

As of Jun 18, Springworks Therapeutics, Inc. has a market capitalization of $3.53 billion, with net sales of $219.67 million and a net profit loss of $253.94 million over the latest four quarters. The company's balance sheet shows shareholder's funds of $481.10 million and total assets of $587.28 million.